Boxer Capital’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Boxer Capital’s Portfolio THRX Stock Details THRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-150,000	Closed	-$404K	–	75
2023 Q3	$404K	Sell	150,000 -200,000	-57%	-$784K	0.02%	69
2023 Q2	$3.27M	Hold	350,000	–	–	0.15%	60
2023 Q1	$3.11M	Sell	350,000 -65,000	-16%	-$638K	0.15%	59
2022 Q4	$2.07M	Sell	415,000 -477,057	-53%	-$2.79M	0.11%	61
2022 Q3	$5.17M	Hold	892,057	–	–	0.29%	53
2022 Q2	$4.93M	Hold	892,057	–	–	0.31%	53
2022 Q1	$10.3M	Hold	892,057	–	–	0.53%	45
2021 Q4	$11.3M	Buy	+892,057	New	+$13.5M	0.44%	43

Other funds holding THRX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Boxer Capital's THRX Position: Q4 2023 in Review

Boxer Capital sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q4 2023, closing a stake of 150,000 shares — an estimated $404K sold.

Boxer Capital first reported a position in THRX in Q4 2021 and held it in 8 quarters. The position peaked at $11.3M in Q4 2021. 70 funds tracked by Wall St. Rank hold THRX as of Q4 2023.

Boxer Capital reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Boxer Capital sold 150,000 Theseus Pharmaceuticals, Inc. Common Stock shares in Q4 2023, an estimated $404K.
Boxer Capital first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 8 quarters.
Boxer Capital's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $11.3M in Q4 2021.
70 funds tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on Boxer Capital's 13F filing for Q4 2023, filed 14 Feb 2024.